TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of
patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain
metastases compared to Osimertinib.